Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C
The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir (DCV+ASV) of M2BPGi levels with...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/6/660 |
| _version_ | 1797530895071051776 |
|---|---|
| author | Satoshi Takakusagi Ken Sato Kyoko Marubashi Kazuko Kizawa Takashi Kosone Satoru Kakizaki Hitoshi Takagi Toshio Uraoka |
| author_facet | Satoshi Takakusagi Ken Sato Kyoko Marubashi Kazuko Kizawa Takashi Kosone Satoru Kakizaki Hitoshi Takagi Toshio Uraoka |
| author_sort | Satoshi Takakusagi |
| collection | DOAJ |
| description | The clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir (DCV+ASV) of M2BPGi levels with those of other fibrosis markers in 73 chronic hepatitis C cases. Moreover, we examined the association between M2BPGi levels and hepatocarcinogenesis in sustained virological response (SVR) and non-SVR cases. M2BPGi levels were significantly improved at post-treatment week 24 (PTW24) in SVR but not non-SVR cases, whereas the changes of other fibrosis markers showed the same tendency in both SVR and non-SVR cases. M2BPGi levels were well correlated with other fibrosis markers at baseline but not PTW24. The incidence of hepatocellular carcinoma (HCC) was significantly associated with M2BPGi levels at PTW24. The achievement of SVR significantly affected the improvement of M2BPGi levels that best reflected the effect of direct-acting antivirals among the fibrosis markers. Furthermore, M2BPGi levels at PTW24 were also associated with the incidence of HCC in only SVR cases. However, the rapid decrease of M2BPGi levels might reflect the amelioration of liver inflammation rather than the improvement of liver fibrosis, which should be further elucidated. |
| first_indexed | 2024-03-10T10:36:30Z |
| format | Article |
| id | doaj.art-d381adfef16a4c98a6390339ed733bbd |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T10:36:30Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-d381adfef16a4c98a6390339ed733bbd2023-11-21T23:17:45ZengMDPI AGBiomedicines2227-90592021-06-019666010.3390/biomedicines9060660Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis CSatoshi Takakusagi0Ken Sato1Kyoko Marubashi2Kazuko Kizawa3Takashi Kosone4Satoru Kakizaki5Hitoshi Takagi6Toshio Uraoka7Department of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, JapanDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, JapanDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, JapanDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, JapanDepartment of Gastroenterology and Hepatology, Kusunoki Hospital, Fujioka, Gunma 375-0024, JapanDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, JapanThe clinical significance of mac-2 binding protein glycosylation isomer (M2BPGi) levels based on virological responses due to antiviral therapy has not been fully evaluated. We compared the change before and 24 weeks after the therapy with daclatasvir and asunaprevir (DCV+ASV) of M2BPGi levels with those of other fibrosis markers in 73 chronic hepatitis C cases. Moreover, we examined the association between M2BPGi levels and hepatocarcinogenesis in sustained virological response (SVR) and non-SVR cases. M2BPGi levels were significantly improved at post-treatment week 24 (PTW24) in SVR but not non-SVR cases, whereas the changes of other fibrosis markers showed the same tendency in both SVR and non-SVR cases. M2BPGi levels were well correlated with other fibrosis markers at baseline but not PTW24. The incidence of hepatocellular carcinoma (HCC) was significantly associated with M2BPGi levels at PTW24. The achievement of SVR significantly affected the improvement of M2BPGi levels that best reflected the effect of direct-acting antivirals among the fibrosis markers. Furthermore, M2BPGi levels at PTW24 were also associated with the incidence of HCC in only SVR cases. However, the rapid decrease of M2BPGi levels might reflect the amelioration of liver inflammation rather than the improvement of liver fibrosis, which should be further elucidated.https://www.mdpi.com/2227-9059/9/6/660mac-2 binding protein glycosylation isomerdirect acting antiviralsliver fibrosishepatocarcinogenesissustained virological response |
| spellingShingle | Satoshi Takakusagi Ken Sato Kyoko Marubashi Kazuko Kizawa Takashi Kosone Satoru Kakizaki Hitoshi Takagi Toshio Uraoka Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C Biomedicines mac-2 binding protein glycosylation isomer direct acting antivirals liver fibrosis hepatocarcinogenesis sustained virological response |
| title | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C |
| title_full | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C |
| title_fullStr | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C |
| title_full_unstemmed | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C |
| title_short | Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C |
| title_sort | impact of m2bpgi on the hepatocarcinogenesis after the combination therapy with daclatasvir and asunaprevir for hepatitis c |
| topic | mac-2 binding protein glycosylation isomer direct acting antivirals liver fibrosis hepatocarcinogenesis sustained virological response |
| url | https://www.mdpi.com/2227-9059/9/6/660 |
| work_keys_str_mv | AT satoshitakakusagi impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT kensato impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT kyokomarubashi impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT kazukokizawa impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT takashikosone impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT satorukakizaki impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT hitoshitakagi impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc AT toshiouraoka impactofm2bpgionthehepatocarcinogenesisafterthecombinationtherapywithdaclatasvirandasunaprevirforhepatitisc |